



#### Fair Market Value Analysis Schedules

Final Report Distributed on Monday, April 20, 2020 Valuation Date: March 16, 2020

# CONTENTS

#### Introduction

**Qualifying Assumptions** 

**Executive Summary** 

**Historical Financials & Operations** 

**Income Approach** 

**Cost of Capital** 

Cost Approach

Market Approach

Scenario Value Calculation

# INTRODUCTION

VMG Holdings LLC d/b/a VMG Health ("VMG" or "we") has been engaged by Stanford Health Care ("Management") to estimate the Fair Market Value of the Total Invested Capital of Stanford Health Care Advantage (the "Business") as of a current date for Management planning purposes.

#### **STANDARD & PREMISE OF VALUE**

The standard of value applicable in this engagement is Fair Market Value ("FMV"). For the purposes of this engagement, FMV is generally defined by the International Glossary of Business Valuation Terms as the price, expressed in terms of cash equivalents, at which a property would change hands between a hypothetical willing and able buyer and a hypothetical willing and able seller, acting at arm's length in an open and unrestricted market, when neither is under compulsion to buy or sell and when both have reasonable knowledge of the relevant facts. The level of value assumed is a fully marketable, controlling ownership interest in the assets of the subject business.

#### **SCOPE OF THE ENGAGEMENT**

This engagement is a Valuation Engagement as generally outlined below:

A "Valuation Engagement" is defined by the American Institute of Certified Public Accountants ("AICPA") Statement on Standards for Valuation Services ("SSVS") No. 1 in VS sec. 100, and establishes standards for the valuation of a business, business ownership interest, security, or intangible asset. This involves an estimate of value of a subject interest applying the valuation approaches and methods deemed appropriate in the circumstances. The Analysis expresses the valuation conclusion as either a single amount or a range. We have not conducted a site review of the subject business premises, nor have we audited or otherwise reviewed the business financial statements, which have been provided by business management and its financial advisors. It was assumed that these financial statements are true and accurate.

#### **INTENDED USERS**

Our report is intended for use solely by Management and only for the indicated purpose. Our analysis is to be used for no other purpose or distributed, in whole or in part, to third parties, other than the Internal Revenue Service, Office of Inspector General, California Department of Managed Health Care ("DMHC"), California Attorney General, and the Centers for Medicare and Medicaid Services ("CMS"). Client may also provide a copy of the report to Essence, its affiliates Essence Group Holdings Corporation and Lumeris Healthcare Outcomes, LLC (collectively, "Essence") and Essence legal counsel. However, Management may not provide the report to any other third party without VMG's written consent. Such consent shall be timely and not unreasonable withheld. The obligation of VMG is solely a corporate obligation, and no officer, principal, director, employee, agent, shareholder, or controlling person shall be subjected to any personal liability whatsoever to any person or entity, nor will any such claim be asserted by or on behalf of any other party to this agreement or any person relying on the opinion.

#### **CERTIFYING & CONTRIBUTING APPRAISERS**

Certifying Appraiser: Colin McDermott, CFA, CPA/ABV Other Contributing Appraisers: Brett Nelson and Henry Smith



# **QUALIFYING ASSUMPTIONS**

#### Amendment of any assumption qualified below could materially impact any conclusions of value presented herein.

- This analysis is intended for use solely by Management and only for the indicated purpose. Our analysis is to be used for no other purpose or distributed, in whole or in part, to third parties, other than the Internal Revenue Service, Office of Inspector General, California Department of Managed Health Care ("DMHC"), California Attorney General, and the Centers for Medicare and Medicaid Services ("CMS"). Client may also provide a copy of the report to Essence, its affiliates Essence Group Holdings Corporation and Lumeris Healthcare Outcomes, LLC (collectively, "Essence") and Essence legal counsel. However, Management may not provide the report to any other third party without VMG's written consent. Such consent shall be timely and not unreasonable withheld. The obligation of VMG is solely a corporate obligation, and no officer, principal, director, employee, agent, shareholder, or controlling person shall be subjected to any personal liability whatsoever to any person or entity, nor will any such claim be asserted by or on behalf of any other party to this agreement or any person relying on the opinion.
- The result of the analysis should not be construed as a fairness opinion or investment recommendation. Nothing contained in this report should be construed as investment, legal, or tax advice. The obligation of VMG is solely a corporate obligation, and no officer, principal, director, employee, agent, shareholder, or controlling person shall be subjected to any personal liability whatsoever to any person or entity, nor will any such claim be asserted by or on behalf of any other party to this agreement or any person relying on the opinion.
- VMG relied upon data provided by Management or obtained from third parties, including accountants, counsel, published sources and commercial databases without audit or verification regarding the accuracy of such information. VMG has not independently audited or confirmed the accuracy of the data provided. We are relying on the data as materially true and correct. To the extent that the information provided to VMG is inaccurate, we reserve the right to amend our analysis accordingly.
- VMG does not assure any forecasted results. Events and circumstances frequently do not occur as expected, actual and expected results may be materially different, and achieving forecasted results depends on the actions, plans, and assumptions of others.
- Total Invested Capital, or TIC, reflects the value of the Business's total debt plus equity and is inclusive of a normalized level of tangible net equity ("TNE"). VMG assumed a normalized level of TNE at approximately 10.6% of Net Operating Revenue based on 200% of the existing required level of TNE.
- Stanford Health Care Advantage's members utilize the Stanford Health Care facility and provider network. This analysis assumes the expense for these services incurred by Stanford Health Care Advantage are arms-length in nature currently and prospectively.
- Management represented the 18 month process to identify a potential partner for the Business included 12 participants with varying levels of interest and proposals. Discussions existed with the following Aetna, United Health, Blue Shield of California, CareMore, Anthem, Bright Health, Hometown Health, Alignment, Lumeris, Sutter, SCAN, and Centene. VMG understands certain payors were interested in arrangements in which the acquiror would assume existing membership and formalize a long-term provider network contract with Stanford Health Care. A single participant pursued extended diligence; however, ultimately decided the Business did not command a positive value given the need to create a California licensure and the local investment required. Management indicate they did not receive a single purchase offer of the existing membership base.
- VMG understands the membership of the Business with transfer to a joint venture with Essence. The indications of fair market value presented in this analysis assume a level of value within the construct of the proposed joint venture (i.e., exisiting membership, provider networks and contracts, administrative cost structure). The proposed transaction is different than verbal indications provided by other participants in the process as Stanford will not have to enter into unfavorable provider network contracts.
- This report was prepared as of March 18, 2020. At the time of this report's release, the economies of the United States is being impacted by the coronavirus ("COVID-19") pandemic. The evolution of the disease, the extent of its economic impact and the results of steps taken and yet to be taken by the federal government and financial institutions are unknown. Healthcare entities may face volume softness with the delay of elective procedures, supply chain disruptions, labor shortages, changes in bad debt, all of which may result in an impact to the business. Therefore, as of the valuation date, the significance and the duration of the COVID-19 pandemic's financial impact is indeterminable and not quantifiable.
- Three distinct approaches to value were considered in accordance with generally accepted valuation methodologies; These approaches include the Cost, Market, and Income Approaches. Ultimately, reliance was placed upon the Cost Approach to value the Business, as it is the approach most often utilized in situations where the estimated FMV of the entity's identifiable tangible and intangible assets produces a value that is greater than the entity's discounted projected cash flow stream.



**EXECUTIVE SUMMARY** 

#### Executive Summary | Fair Market Value Analysis Summary

Conclusion of Value <sup>(1)(2)</sup>		Rounded
Fair Market Value of the Total Invested Capital including Normalized Tangible Net Equity <i>(Rounded)</i> Plus: Excess Tangible Net Equity		\$4,420,000 \$820,000
Adjusted Fair Market Value of the Total Invested Capital including Excess Tangible Net Equity (Rounde	d)	\$5,240,000
Less: Assets Retained by Stanford Health Care		(5,240,000
Adjusted Fair Market Value of the Stanford Health Care Contribution to the Joint Venture (Rounded)		\$0
Implied Market Multiples <sup>(1)</sup>	Financial Metric	Mid-Point
TIC / Normalized Base Year Membership	3,800	\$1,163

#### Notes & Sources

(1) Total Invested Capital ("TIC") as reflected above represents all working assets utilized in the operation of the Business.

(2) Please note that all dollar figures presented above are rounded.



#### **Executive Summary | Value Reconciliation**

Mid-Point Value Indications by Methodology $^{(1)}$ $^{(2)}$	Value	Weight	Conclusion	Key Assumptions
Income Approach	n/a	-	-	Discounted Cash Flow Analysis
Cost Approach	\$4,420,000	100.0%	\$4,420,000	Build-Up Approach
Market Approach - EBITDA	n/a	-	-	Merger & Acquisition Method
Market Approach - Membership	n/a	-	-	Merger & Acquisition Method
Mid-Point Fair Market Value Indication			\$4,420,000	

#### Notes & Sources

(1) Three distinct approaches to value were considered in accordance with generally accepted valuation methodologies; These approaches include the Cost, Market, and Income Approaches. Ultimately, reliance was placed upon the Cost Approach to value the Business. VMG did not rely on the value indication produced by the Income Approach due to the projected negative cash flows. Management indicated the operations of the Business are unlikely to yield positive cash flow in absence of increased membership growth to leverage the existing administrative expenses. Further, management indicated that the necessary membership growth is unlikely given the existing Stanford Health Care facility and provider network. The Market Approach was not relied up as the Business is not projected to have positive EBITDA and membership multiples where not considered given the process run by Management and the lack of resulting interest in the Business.

(2) All value indications include a normalized level of working capital.



#### **HISTORICAL FINANCIALS & OPERATIONS**

#### STANFORD HEALTH CARE ADVANTAGE Historical Financials & Operations | Balance Sheet

	Footnotes	CY 2017	CY 2018	CY 2019	CY 2017	CY 2018	CY 2019
\ssets							
Current Assets							
Cash & Cash Equivalents		\$7,882,513	\$13,865,977	\$11,863,373	90.6%	90.6%	79.2
Other Receivables		257,680	1,088,225	2,725,885	3.0%	7.1%	18.2
Prepaid Expenses and Other		252,399	38,701	56,184	2.9%	0.3%	0.4
		8,392,592	14,992,903	14,645,442	96.4%	98.0%	97.8
Other Assets							
Deposit		311,746	311,766	327,010	3.6%	2.0%	2.2
		311,746	311,766	327,010	3.6%	2.0%	2.2
otal Assets		\$8,704,338	\$15,304,669	\$14,972,452	100.0%	100.0%	100.0
Growth		n/a	75.8%	(2.2%)			
iabilities & Shareholders' Equity							
Current Liabilities							
Accounts Payable and Accrued Liabilities		3,953,144	7,713,398	8,247,693	45.4%	50.4%	55.1
Due to Related Parties		2,381,935	3,407,803	1,483,030	27.4%	22.3%	9.9
		6,335,079	11,121,201	9,730,723	72.8%	72.7%	65.0
Equity							
Member Equity	1	2,369,259	4,183,468	5,241,729	27.2%	27.3%	35.0
		2,369,259	4,183,468	5,241,729	27.2%	27.3%	35.0
otal Liabilities & Equity		\$8,704,338	\$15,304,669	\$14,972,452	100.0%	100.0%	100.0
otal Liabilities & Equity Growth		<b>\$8,704,338</b> n/a	<b>\$15,304,669</b> 75.8%	<b>\$14,972,452</b> (2.2%)	100.0%	100.0%	100.0
	1				100.0%	100.0%	100.0
	1	n/a	75.8%	(2.2%)	100.0%	100.0%	100.0

#### Notes & Sources

Sources: We have utilized unaudited financials provided by Business management for the calendar years ended 2017 ("CY 2017"), CY 2018, and CY 2019.

(1) Minimum tangible net equity is approximately 8.0% of annualized non-capitated health care expenditures.



#### Historical Financials & Operations | Reported Net Working Capital

		CY 2017	CY 2018	CY 2019
Current Assets				
Cash & Cash Equivalents		\$7,882,513	\$13,865,977	\$11,863,373
Other Receivables		257,680	1,088,225	2,725,885
Prepaid Expenses and Other		252,399	38,701	56,184
		\$8,392,592	\$14,992,903	\$14,645,442
Current Liabilities				
Accounts Payable and Accrued Liabilities		\$3,953,144	\$7,713,398	\$8,247,693
Due to Related Parties		2,381,935	3,407,803	1,483,030
		\$6,335,079	\$11,121,201	\$9,730,723
Reported Net Working Capital		\$2,057,513	\$3,871,702	\$4,914,719
Total Net Operating Revenue		\$17,057,871	\$28,586,553	\$41,525,417
Reported Net Working Capital as a Percentage of Total Net Operating Revenue		12.1%	13.5%	11.8%
Required Tangible Net Equity	1	\$1,343,870	\$2,083,976	\$2,209,212
Actual Tangible Net Equity		2,369,259	4,183,468	5,241,729
Excess Tangible Net Equity		\$1,025,389	\$2,099,492	\$3,032,517
Required Tangible Net Equity as a Percentage of Total Net Operating Revenue		7.9%	7.3%	5.3%
Selected Tangible Net Equity as a Percentage of Total Net Operating Revenue				10.6%
Selected Tangible Net Equity				\$4,418,424

#### Notes & Sources

Sources: We have utilized unaudited financials provided by Business management for the calendar years ended 2017 ("CY 2017"), CY 2018, and CY 2019.

(1) Minimum tangible net equity is approximately 8.0% of annualized non-capitated health care expenditures.



#### Historical Financials & Operations | Income Statement

						Common Size		Per N	lember Per N	lonth
	Footnotes	CY 2017	CY 2018	CY 2019	CY 2017	CY 2018	CY 2019	CY 2017	CY 2018	CY 2019
evenues										
Premium Revenue		\$17,057,871	\$28,586,553	\$41,062,917	100.0%	100.0%	98.9%	\$750.98	\$828.57	\$904.9
Optional Supplemental Benefits		-	-	462,500	-	-	1.1%	-	-	\$10.1
Total Net Operating Revenue		17,057,871	28,586,553	41,525,417	100.0%	100.0%	100.0%	\$750.98	\$828.57	\$915.1
Growth		n/a	67.6%	45.3%						
perating Expenses										
Medical Expense										
Capitation		5,444,735	8,153,158	12,321,846	31.9%	28.5%	29.7%	\$239.71	\$236.32	\$271.
Inpatient & SNF Claims		7,806,985	12,666,482	12,546,880	45.8%	44.3%	30.2%	\$343.71	\$367.13	\$276.
Outpatient & Professional Claims		4,513,113	8,759,548	9,475,525	26.5%	30.6%	22.8%	\$198.69	\$253.89	\$208.
Out of Network Claims		1,995,852	2,523,691	3,196,116	11.7%	8.8%	7.7%	\$87.87	\$73.15	\$70.4
Claim Refunds & Recoveries		(99,849)	(801,872)	(809,846)	(0.6%)	(2.8%)	(2.0%)	(\$4.40)	(\$23.24)	(\$17.
Pharmacy Claims - Part B		235,498	229,716	554,480	1.4%	0.8%	1.3%	\$10.37	\$6.66	\$12.
Pharmacy Claims - Part D		2,108,854	2,907,365	3,828,366	12.4%	10.2%	9.2%	\$92.84	\$84.27	\$84.
Optional Supplemental Benefits Expense		-	-	652,792		-	1.6%	-	-	\$14.
		22,005,188	34,438,088	41,766,159	129.0%	120.5%	100.6%	\$968.79	\$998.18	\$920.4
General & Administrative										
Salaries, Wages, and Benefits		2,653,492	3,172,432	2,760,312	15.6%	11.1%	6.6%	\$116.82	\$91.95	\$60.
Customer Service (Care Counsel)		465,707	377,910	691,606	2.7%	1.3%	1.7%	\$20.50	\$10.95	\$15.
Purchased Services (Clinical, Rx, Admin, Misc)		792,859	534,462	1,331,317	4.6%	1.9%	3.2%	\$34.91	\$15.49	\$29.
Commissions		796,693	1,256,615	1,935,953	4.7%	4.4%	4.7%	\$35.07	\$36.42	\$42.
WiPro		390,400	346,220	616,050	2.3%	1.2%	1.5%	\$17.19	\$10.04	\$13.
Professional Fees		256,440	889,572	1,013,727	1.5%	3.1%	2.4%	\$11.29	\$25.78	\$22.
Marketing & Outreach		320,546	335,010	228,201	1.9%	1.2%	0.5%	\$14.11	\$9.71	\$5.
Occupancy Expense		70,638	75,765	65,255	0.4%	0.3%	0.2%	\$3.11	\$2.20	\$1.
Insurance		264,768	220,472	291,187	1.6%	0.8%	0.7%	\$11.66	\$6.39	\$6.
Other	(=)	108,055	206,182	293,383	0.6%	0.7%	0.7%	\$4.76	\$5.98	\$6.
	(2)	6,119,598	7,414,640	9,226,991	35.9%	25.9%	22.2%	\$269.42	\$214.91	\$203.
Total Operating Expenses		28,124,786	41,852,728	50,993,150	164.9%	146.4%	122.8%	\$1,238.21	\$1,213.09	\$1,123.
Growth		n/a	48.8%	21.8%						
BITDA		(11,066,915)	(13,266,175)	(9,467,733)	(64.9%)	(46.4%)	(22.8%)	(\$487.23)	(\$384.52)	(\$208.0
Growth		(nmf)	(nmf)	nmf		. ,	,		,	

#### Notes & Sources

(1) Sources: We have utilized unaudited financials provided by Business management for the calendar years ended 2017 ("CY 2017"), CY 2018, and CY 2019.

(2) Note: The admin. expense detail as presented in the "2018-12 SCH Advantage Financial Package" and "2019-12 SHC Advantage Financial Package" files are not consistent with the summary level statements as presented in the same documents. Presented above are the administrative expenses per the detailed breakout.



#### **STANFORD HEALTH CARE ADVANTAGE** Historical Financials & Operations | Volume Analysis

		Gross		Per N	lember Per Mo	nth
Statistics	CY 2017	CY 2018	CY 2019	CY 2017	CY 2018	CY 2019
Member Months	22,714	34,501	45,375	22,714	34,501	45,375
Implied Average Membership	1,893	2,875	3,781	1,893	2,875	3,781
Growth	n/a	51.9%	31.5%	n/a	51.9%	31.5%
Revenue						
Premium Revenue	\$17,057,871	\$28,586,553	\$41,062,917	\$750.98	\$828.57	\$904.97
Growth	n/a	67.6%	43.6%	n/a	10.3%	9.2%
Optional Supplemental Benefits	-	-	462,500	-	-	\$10.19
Growth	n/a	n/a	n/a	n/a	n/a	n/a
Total Net Operating Revenue	\$17,057,871	\$28,586,554	\$41,525,417	\$750.98	\$828.57	\$915.16
Growth	n/a	67.6%	45.3%	n/a	10.3%	10.5%
Expenses						
Medical Expense	\$22,005,188	\$34,438,088	\$41,766,159	\$968.79	\$998.18	\$920.47
Growth	n/a	56.5%	21.3%	n/a	3.0%	(7.8%)
General & Administrative	6,119,598	7,414,640	9,226,991	\$269.42	\$214.91	\$203.35
Growth	n/a	21.2%	24.4%	n/a	(20.2%)	(5.4%)
Total Operating Expense	\$28,124,786	\$41,852,728	\$50,993,150	\$1,238.21	\$1,213.09	\$1,123.82
Growth	n/a	48.8%	21.8%	n/a	(2.0%)	(7.4%)
EBITDA	(\$11,066,915)	(\$13,266,174)	(\$9,467,733)	(\$487.23)	(\$384.52)	(\$208.66)
Growth	n/a	(nmf)	nmf	n/a	nmf	nmf
Medical Loss Ratio	129.0%	120.5%	100.6%			
Administrative Cost Ratio	35.9%	25.9%	22.2%			
EBITDA	(64.9%)	(46.4%)	(22.8%)			
Medicare Star Rating	3.5	3.5	3.0			
Risk Adjustment Factor ("RAF") Score	0.79	0.83	1.00	CONFIDENTIAL		
Required Tangible Net Equity	\$1,343,870	\$2,083,976	\$2,209,212	\$59.16	\$60.40	\$48.69
Actual Tangible Net Equity	2,369,259	4,183,468	5,241,729	\$104.31	\$121.26	\$115.52
Excess Tangible Net Equity	\$1,025,389	\$2,099,492	\$3,032,517	\$45.14	\$60.85	\$66.83

#### Notes & Sources

Source: Management provided financial statements and operational reports for the calendar years ended December 31, 2017 ("CY 2017"), CY 2018, and CY 2019.


Scenario Value Calculation | Budget Comparison

	Actual	Budget	Commo	n Size	Per Member F	er Month
Footnotes	CY 2019	CY 2020	CY 2019	CY 2020	CY 2019	CY 2020
Member Months	45,375	61,800	45,375	61,800	45,375	61,800
Growth	n/a	36.2%	n/a	36.2%	n/a	36.2%
Revenues						
Premium Revenue	\$41,062,917	\$53,979,424	98.9%	98.8%	\$904.97	\$873.45
Optional Supplemental Benefits	462,500	635,020	1.1%	1.2%	\$10.19	\$10.28
Total Net Operating Revenue	41,525,417	54,614,444	100.0%	100.0%	\$915.16	\$883.73
Growth	n/a	31.5%			n/a	(3.4%)
Operating Expenses						
Medical Expense						
Capitation						
Inpatient & SNF Claims						
Outpatient & Professional Claims						
Out of Network Claims						
Claim Refunds & Recoveries						
CMS Part C Revenue						
Pharmacy Claims - Part B						
Pharmacy Claims - Part D						
Optional Supplemental Benefits Expense						
Total Medical Expense	41,766,159	57,243,856	100.6%	104.8%	\$920.47	\$926.28
Growth	n/a	37.1%			n/a	0.6%
General & Administrative						
Salaries, Wages, and Benefits						
Customer Service (Care Counsel)						
Purchased Services (Clinical, Rx, Admin, Misc)						
Commissions						
WiPro						
Professional Fees						
Marketing & Outreach						
Occupancy Expense						
Insurance						
Other						
Total Medical Expense	9,226,991	10,778,954	22.2%	19.7%	\$203.35	\$174.42
Growth	n/a	16.8%			n/a	(14.2%)
Total Operating Expenses	50,993,150	68,022,810	122.8%	124.6%	\$1,123.82	\$1,100.69
Growth	n/a	33.4%			n/a	(2.1%)
EBITDA	(\$9,467,733)	(\$13,408,365)	(22.8%)	(24.6%)	(\$208.66)	(\$216.96)
Growth	(nmf)	(nmf)			(nmf)	(nmf)

#### Notes & Sources

(1) Management provided financial statements for CY 2019 as well as a budget for the calander year ended December 31, 2020 ("CY 2020").

(2) Source: "FY 20 SA Forecast Model\_20190625 7pm" file provided by management.



#### Notes & Sources

(1) Per the "7.4\_Org Backgrnd Structure\_July 2018" file provided by management.



**INCOME APPROACH** 

#### Income Approach | Development of the Normalized Base Year

Footnotes	CY 2017	CY 2018	CY 2019	Adjustments	NBY	CY 2017	CY 2018	CY 2019	NBY
Revenues									
Premium Revenue	\$17,057,871	\$28,586,553	\$41,062,917	-	\$41,062,917	100.0%	100.0%	98.9%	98.9%
Optional Supplemental Benefits	-	-	\$462,500	-	462,500	-	-	1.1%	1.1%
Total Net Operating Revenue	17,057,871	28,586,553	41,525,417	-	41,525,417	100.0%	100.0%	100.0%	100.0%
Operating Expenses									
Medical Expense									
Capitation	5,444,735	8,153,158	12,321,846	_	12,321,846	31.9%	28.5%	29.7%	29.7%
Inpatient & SNF Claims	7,806,985	12,666,482	12,546,880	-	12,546,880	45.8%	44.3%	30.2%	30.2%
Outpatient & Professional Claims	4,513,113	8,759,548	9,475,525	-	9,475,525	26.5%	30.6%	22.8%	22.8%
Out of Network Claims	1,995,852	2,523,691	3,196,116	-	3,196,116	11.7%	8.8%	7.7%	7.7%
Claim Refunds & Recoveries	(99,849)	(801,872)	(809,846)	-	(809,846)	(0.6%)	(2.8%)	(2.0%)	(2.0%)
Pharmacy Claims - Part B	235,498	229,716	554,480	-	554,480	1.4%	0.8%	1.3%	1.3%
Pharmacy Claims - Part D	2,108,854	2,907,365	3,828,366	-	3,828,366	12.4%	10.2%	9.2%	9.2%
Optional Supplemental Benefits Expense	-	-	652,792	-	652,792	-	-	1.6%	1.6%
	22,005,188	34,438,088	41,766,159	-	41,766,159	129.0%	120.5%	100.6%	100.6%
General & Administrative									
Salaries, Wages, and Benefits	2,653,492	3,172,432	2,760,312	-	2,760,312	15.6%	11.1%	6.6%	6.6%
Customer Service (Care Counsel)	465,707	377,910	691,606	-	691,606	2.7%	1.3%	1.7%	1.7%
Purchased Services (Clinical, Rx, Admin, Misc)	792,859	534,462	1,331,317	-	1,331,317	4.6%	1.9%	3.2%	3.2%
Commissions	796,693	1,256,615	1,935,953	-	1,935,953	4.7%	4.4%	4.7%	4.7%
WiPro	390,400	346,220	616,050	-	616,050	2.3%	1.2%	1.5%	1.5%
Professional Fees	256,440	889,572	1,013,727	-	1,013,727	1.5%	3.1%	2.4%	2.4%
Marketing & Outreach	320,546	335,010	228,201	-	228,201	1.9%	1.2%	0.5%	0.5%
Occupancy Expense	70,638	75,765	65,255	-	65,255	0.4%	0.3%	0.2%	0.2%
Insurance	264,768	220,472	291,187	-	291,187	1.6%	0.8%	0.7%	0.7%
Other	108,055	206,182	293,383	-	293,383	0.6%	0.7%	0.7%	0.7%
	6,119,598	7,414,640	9,226,991	-	9,226,991	35.9%	25.9%	22.2%	22.2%
Total Operating Expenses	28,124,786	41,852,728	50,993,150	-	50,993,150	164.9%	146.4%	122.8%	122.8%
EBITDA	(11,066,915)	(13,266,175)	(9,467,733)	-	(9,467,733)	(64.9%)	(46.4%)	(22.8%)	(22.8%)

#### Notes & Sources

(1) The Normalized Base Year (the "NBY") is based on the CY 2019 income statement. The NBY eliminates any unusual or non-recurring items from revenue and expenses.



Strictly Private & Confidential | 16

#### Income Approach | Revenue Assumptions

						1	Projection Period			
	CY 2017	CY 2018	CY 2019	NBY	Year 1	Year 2	Year 3	Year 4	Year 5	Key Assumptions
Revenue										
Estimated Member Months	22,714	34,501	45,375	45,375	55,117	66,952	81,327	98,789	120,000	Assumed membership increases to 10,000 covered
Growth	n/a	51.9%	31.5%	-	21.5%	21.5%	21.5%	21.5%	21.5%	lives by Yr. 5
Average Net Revenue per Member Month	\$750.98	\$828.57	\$904.97	\$904.97	\$923.07	\$941.53	\$960.36	\$979.57	\$999.16	
Growth	n/a	10.3%	9.2%	-	2.0%	2.0%	2.0%	2.0%	2.0%	
Nedicare Advantage Net Premium Revenue	\$17,057,871	\$28,586,553	\$41,062,917	\$41,062,917	\$50,877,127	\$63,036,974	\$78,103,075	\$96,770,038	\$119,898,483	
Optional Supplemental Benefits	-	-	462,500	462,500	462,500	462,500	462,500	462,500	462,500	No Growth
Total Net Operating Revenue	\$17,057,871	\$28,586,553	\$41,525,417	\$41,525,417	\$51,339,627	\$63,499,474	\$78,565,575		\$120,360,983	
Growth	n/a	67.6%	45.3%	-	23.6%	23.7%	23.7%	23.8%	23.8%	
Medical Expenses										
Capitation	\$5,444,735	\$8,153,158	\$12,321,846	\$12,321,846						Management represented that Year 5 MLR of
npatient & SNF Claims	7,806,985	12,666,482	12,546,880	12,546,880						90.0% is achievable with increased care
Outpatient & Professional Claims	4,513,113	8,759,548	9,475,525	9,475,525						management and care coordination efforts.
Dut of Network Claims	1,995,852	2,523,691	3,196,116	3,196,116						Projected expenses reflect existing contractual
Claim Refunds & Recoveries	(99,849)	(801,872)	(809,846)	(809,846)						rates with health care providers.
Pharmacy Claims - Part B	235,498	229,716	554,480	554,480						
Pharmacy Claims - Part D	2,108,854	2,907,365	3,828,366	3,828,366						The improvement in MLR is forecasted linearly
-	2,100,034	2,507,505								over the five year discrete forecast.
Optional Supplemental Benefits Expense	\$22,005,188	\$34,438,088	652,792 \$41,766,159	652,792 \$41,766,159	\$50,550,946	\$61,180,376	\$74,033,833	\$89,566,675	\$108,324,885	
Medical Loss Ratio ("MLR")	129.0%	120.5%	100.6%	100.6%	98.5%	96.3%	94.2%	92.1%	90.0%	` Per Management
Growth	n/a	(6.6%)	(16.5%)	n/a	(2.1%)	(2.1%)	(2.2%)	(2.2%)	(2.3%)	
Administrative Expenses										
Salaries, Wages, and Benefits	\$2,653,492	\$3,172,432	\$2,760,312	\$2,760,312						Management represented that Year 5 ACR of
Customer Service (Care Counsel)	465,707	377,910	691,606	691,606						17.0% is achievable given the projected decline in
Purchased Services (Clinical, Rx, Admin, Misc)	792,859	534,462	1,331,317	1,331,317						medical loss ratios.
Commissions	796,693	1,256,615	1,935,953	1,935,953						
ViPro	390,400	346,220	616,050	616,050						The improvement in ACR is forecasted linearly
	,									over the five year discrete forecast.
Professional Fees	256,440	889,572	1,013,727	1,013,727						· · · ·
Marketing & Outreach	320,546	335,010	228,201	228,201						
Occupancy Expense	70,638	75,765	65,255	65,255						
Insurance	264,768	220,472	291,187	291,187						
Other	108,055	206,182	293,383	293,383						
	\$6,119,598	\$7,414,640	\$9,226,991	\$9,226,991	\$10,871,722	\$12,783,754	\$14,996,630	\$17,544,659	\$20,461,367	
Administrative Cost Ratio ("ACR")	35.9%	25.9%	22.2%	22.2%	21.2%	20.1%	19.1%	18.0%	17.0%	Per Management
Growth	n/a	(27.7%)	(14.3%)	-	(4.7%)	(4.9%)	(5.2%)	(5.5%)	(5.8%)	
EBITDA	(\$11,066,915)	(\$13,266,175)	(\$9,467,733)	(\$9,467,733)	(\$10,083,041)	(\$10,464,656)	(\$10,464,888)	(\$9,878,797)	(\$8,425,269)	
EBITDA Margin	(64.9%)	(46.4%)	(22.8%)	(22.8%)	(19.6%)	(16.5%)	(13.3%)	(10.2%)	(7.0%)	



#### Income Approach | Discounted Cash Flow Assumptions

#### **Discounted Cash Flow Analysis Assumptions**

<ul> <li>Selected Incremental Net Working Capital Requirements as a Percentage of Total Net Operating Revenue</li> <li>Inflation Rate</li> </ul>	10.6% 3.0%
Terminal Growth Rate     Tax Rate	2.0% 28.0%
Tax Rate     Depreciation Assumptions	28.0%

<ul> <li>Net Initial Depreciable Basis of Furniture, Fixtures, Equipment &amp; Leasehold Improvements</li> </ul>	-
<ul> <li>Estimated Useful Life of Initial Furniture, Fixtures, Equipment &amp; Leasehold Improvements</li> </ul>	7.0
<ul> <li>Estimated Useful Life of Projected Furniture, Fixtures, Equipment &amp; Leasehold Improvement Expenditures</li> </ul>	10.0

Projected Capital Expenditures & Depreciation Expense <sup>(1), (2)</sup>	Year 1	Year 2	Year 3	Year 4	Year 5	Terminal Year
Capital Expenditures & Improvements						
Furniture, Fixtures, Equipment & Leasehold Improvements	-	-	-	-	-	-
Real Estate	-	-	-	-	-	-
Total Capital Expenditures	-	-	-	-	-	-
As a Percentage of Total Net Operating Revenue	-	-	-	-	-	-
Depreciation Schedule						
Depreciation of Initial Net Fixed Assets	-	-	-	-	-	
Calculated Depreciation of Capital Expenditures	-	-	-	-	-	
Total Depreciation	-	-	-	-	-	-

#### Notes & Sources

(1) No discrete capital is projected as it is assumed to be captured in the administrative cost ratio charge.

(2) Projected Depreciation & Amortization expense was based on the Tax Cut and Jobs Act signed into law on December 22, 2017. Depreciation was modeled assuming a hypothetical control transaction using an asset deal structure. A hypothetical buyers is assumed to take full advantage of this new law and, therefore, depreciation expense in Year One includes the full expensing of acquired net fixed assets plus the full expensing of any capital expenditures. Depreciation in Year 2 through Year 5 assumes full expensing for all assets with tax lives of 15.0 years or less, including qualified leasehold improvements. Please note, this bonus depreciation is subject to phase-out in the future.



#### Income Approach | Cash Flow Projections

					I			Projection	Period		
	CY 2017	CY 2018	CY 2019	CY 2019	NBY	Year 1	Year 2	Year 3	Year 4	Year 5	Terminal Year
Revenues					Í						
Premium Revenue	\$17,057,871	\$28,586,553	\$41,062,917	\$41,062,917	\$41,062,917	\$50,877,127	\$63,036,974	\$78,103,075	\$96,770,038	\$119,898,483	
Optional Supplemental Benefits	-	-	462,500	462,500	462,500	462,500	462,500	462,500	462,500	462,500	
Total Net Operating Revenue	17,057,871	28,586,553	41,525,417	41,525,417	41,525,417	51,339,627	63,499,474	78,565,575	97,232,538	120,360,983	122,768,203
Growth	n/a	67.6%	45.3%	-	-	23.6%	23.7%	23.7%	23.8%	23.8%	2.0%
Operating Expenses											
Medical Expense	22,005,188	34,438,088	41,766,159	41,766,159	41,766,159	50,550,946	61,180,376	74,033,833	89,566,675	108,324,885	
General & Administrative	6,119,598	7,414,640	9,226,991	9,226,991	9,226,991	10,871,722	12,783,754	14,996,630	17,544,659	20,461,367	
Total Operating Expenses	28,124,786	41,852,728	50,993,150	50,993,150	50,993,150	61,422,668	73,964,130	89,030,463	107,111,335	128,786,252	
Growth	n/a	48.8%	21.8%	-	-	20.5%	20.4%	20.4%	20.3%	20.2%	
EBITDA	(11,066,915)	(13,266,175)	(9,467,733)	(9,467,733)	(9,467,733)	(10,083,041)	(10,464,656)	(10,464,888)	(9,878,797)	(8,425,269)	(8,593,774)
Growth	(nmf)	(nmf)	nmf	(nmf)	(nmf)	(nmf)	(nmf)	(nmf)	nmf	nmf	2.0%
Depreciation & Amortization Expense	-	-	-	-	-	-	-	-	-	-	-
Interest Expense	-	-	-	-	-	-	-	-	-	-	-
Earnings Before Income Taxes	(11,066,915)	(13,266,175)	(9,467,733)	(9,467,733)	(9,467,733)	(10,083,041)	(10,464,656)	(10,464,888)	(9,878,797)	(8,425,269)	(8,593,774)
Federal & State Income Tax Expense	-	-	-	-	-	-	-	-	-	-	-
Earnings After Income Taxes	(\$11,066,915)	(\$13,266,175)	(\$9,467,733)	(\$9,467,733)	(\$9,467,733)	(\$10,083,041)	(\$10,464,656)	(\$10,464,888)	(\$9,878,797)	(\$8,425,269)	(\$8,593,774)

#### Income Approach | Cash Flow Projections

								Projection	n Period		
	CY 2017	CY 2018	CY 2019	CY 2019	NBY	Year 1	Year 2	Year 3	Year 4	Year 5	Terminal Year
Revenues											
Premium Revenue	100.0%	100.0%	98.9%	98.9%	98.9%	99.1%	99.3%	99.4%	99.5%	99.6%	
Optional Supplemental Benefits	-	-	1.1%	1.1%	1.1%	0.9%	0.7%	0.6%	0.5%	0.4%	
Total Net Operating Revenue	100.0%	100.0%	100.0%	100.0%	100.0%	100.0%	100.0%	100.0%	100.0%	100.0%	100.0%
Operating Expenses											
Medical Expense	129.0%	120.5%	100.6%	100.6%	100.6%	98.5%	96.3%	94.2%	92.1%	90.0%	
General & Administrative	35.9%	25.9%	22.2%	22.2%	22.2%	21.2%	20.1%	19.1%	18.0%	17.0%	
Total Operating Expenses	164.9%	146.4%	122.8%	122.8%	122.8%	119.6%	116.5%	113.3%	110.2%	107.0%	
EBITDA	(64.9%)	(46.4%)	(22.8%)	(22.8%)	(22.8%)	(19.6%)	(16.5%)	(13.3%)	(10.2%)	(7.0%)	(7.0%
Depreciation & Amortization Expense	-	-	-	-	-	-	-	-	-	-	-
Interest Expense	-	-	-	-	-	-	-	-	-	-	-
Earnings Before Income Taxes	(64.9%)	(46.4%)	(22.8%)	(22.8%)	(22.8%)	(19.6%)	(16.5%)	(13.3%)	(10.2%)	(7.0%)	(7.0%
Federal & State Income Tax Expense	-	-	-	-	-	-	-	-	-	-	-
Earnings After Income Taxes	(64.9%)	(46.4%)	(22.8%)	(22.8%)	(22.8%)	(19.6%)	(16.5%)	(13.3%)	(10.2%)	(7.0%)	(7.0%

#### Income Approach | Discounted Cash Flow Analysis

	Year 1	Year 2	Year 3	Year 4	Year 5	Terminal Year	Key Assumptions
EBITDA	(\$10,083,041)	(\$10,464,656)	(\$10,464,888)	(\$9,878,797)	(\$8,425,269)	(\$8,593,774)	
Depreciation & Amortization Expense	-	-	-	-	-	-	
Earnings Before Income Taxes	(10,083,041)	(10,464,656)	(10,464,888)	(9,878,797)	(8,425,269)	(8,593,774)	
Federal & State Income Tax Expense	-	-	-	-	-	-	28.0% Blended Federal & State Tax Rate
Earnings After Income Taxes	(10,083,041)	(10,464,656)	(10,464,888)	(9,878,797)	(8,425,269)	(8,593,774)	
Plus: Depreciation & Amortization	-	-	-	-	-	-	
Less: Required Annual Capital Expenditures	-	-	-	-	-	-	
Less: Incremental Working Capital Requirements	(1,044,260)	(1,293,843)	(1,603,077)	(1,986,219)	(2,460,933)	(256,135)	10.6% of Total Net Operating Revenues
Net Discretionary Cash Flow	(11,127,301)	(11,758,499)	(12,067,964)	(11,865,015)	(10,886,202)	(8,849,909)	
				Indicated	Residual Value:	(68,076,226)	2.0% Long-Term Growth Rate
Present Value Period (Mid-Year Convention)	0.50	1.50	2.50	3.50	4.50	4.50	
Present Value Factor	0.9325	0.8109	0.7051	0.6131	0.5332	0.5332	15.0% Weighted Average Cost of Capital
Discounted Net Discretionary Cash Flows	(\$10,376,262)	(\$9,534,658)	(\$8,509,213)	(\$7,274,881)	(\$5,804,116)	(\$36,295,701)	
Sum of the Present Value of the Years One through Five Pro	jected Cash Flows				(\$41,499,131)	-	
Present Value of the Terminal Year					(\$36,295,701)	-	
Mid-Point Fair Market Value Indication					nmf	-	

Please note, VMG did not rely on the value indication produced by the Income Approach due to the projected negative cash flows. Management indicated the operations of the Business are unlikely to yield positive cash flow in absence of increased membership growth to leverage the existing administrative expenses. Further, management indicated that the necessary membership growth is unlikely given the existing Stanford Health Care facility and provider network.



**COST OF CAPITAL** 

#### **STANFORD HEALTH CARE ADVANTAGE Cost of Capital | Capital Asset Pricing Model**

	Footnotes		Key Assumptions
Cost of Equity			$K_e = R_f + [R_m \times B_i] + R_s + R_u$
Market Risk Premium (R <sub>M</sub> )	1	6.00%	Based upon VMG's review of published articles and academic studies.
$x$ Subject Company Re-levered Beta $(B_i)$	2	0.9355	Please refer to the Beta Calculation page for more detail.
Adjusted Market Risk Premium		5.61%	
+ Size Premium (R <sub>s</sub> )	3	5.37%	Duff & Phelps: 2018 Valuation Handbook, Market Capitalization of companies in the 10th Decile.
+ Company Specific Risk Premium (R <sub>u</sub> )	4	6.00%	
Total Estimated Equity Risk Premium		16.98%	
+ Risk-Free Rate of Return (R <sub>F</sub> )	5	1.10%	Yield of 20 Year Treasury securities as of March 16, 2020, as published by the Federal Reserve.
Total Cost of Equity (K <sub>e</sub> )		18.08%	
$x$ Equity as a Percentage of Total Capital (W_e)	6	80.00%	
Pro-Rata Cost of Equity		14.47%	
Cost of Debt			
Pre-Tax Cost of Debt (K <sub>d</sub> )	7	4.08%	Moody's yield on corporate bonds, rating Baa, as of March 16, 2020, as published by the Federal Reserve.
x Tax Rate (t)	8	27.98%	Blended state and federal tax rate for businesses operating in the state of California.
After-Tax Cost of Debt		2.94%	After-Tax Cost of Debt = Pre-Tax Cost of Debt * (1-Tax Rate)

0.59%

x Debt as a Percentage of Total Capital (W<sub>d</sub>) 6 20.00% Pro-Rata Cost of Debt

Blended state and federal tax rate for businesses operating in the state of California.	
After-Tax Cost of Debt = Pre-Tax Cost of Debt * (1-Tax Rate)	
The selected debt weighting is based on the Industry Norm.	

#### Weighted Average Cost of Capital

#### Pro-Rata Cost of Equity 14.47% Pro-Rata Cost of Debt 0.59% Weighted Average Cost of Capital (Rounded) 15.00%

WACC =	ί Κ ္	х	W	]+	[Ка	х	(1-t	) x	W	4	1
	e e		•• e		L'' (1		( - 0	/ ^		0	4

#### Cost of Capital | Capital Asset Pricing Model

					Company-Specific Risk Premiu						
		5.0%	5.5%	6.0%	6.5%	7.0%					
	10.0%	15.0%	15.5%	16.0%	16.5%	17.0%					
	15.0%	14.5%	15.0%	15.5%	16.0%	16.5%					
TIC	20.0%	14.5%	14.5%	15.0%	15.5%	16.0%					
bt/	25.0%	14.0%	14.0%	14.5%	15.0%	15.5%					
Debt,	30.0%	13.5%	13.5%	14.0%	14.5%	14.5%					

#### Notes & Sources

- (1) The equity risk premium is the additional return an investor expects to receive to compensate for the risk associated with investing in equities as opposed to investing in riskless assets. The equity risk premium applied was selected based upon VMG's review of published articles and academic studies that attempt to quantify the expected market risk premium for United States common stocks by utilizing both historical and forward-looking sources. The selected equity risk premium was considered to reasonably represent a consensus viewpoint of the market equity risk premium.
- (2) The beta is a measure of statistical volatility, or systemic risk, of an industry relative to the market as a whole. Beta is used to measure the price sensitivity of a company, or in this case an industry, in relation to changes in overall market prices. Public guideline company betas are unlevered in order to remove any positive effects they might receive by adding debt to their capital structures. These unlevered betas are then re-levered using the selected capital structure for the entity under question. Please refer to the following page for the publicly-traded guideline companies utilized and our calculation of beta.
- (3) The small company (or small size) premium is the additional return an investor expects to receive to compensate for the additional risk associated with investing in a small, and inherently more risky, company. The small size risk premium utilized was the risk premium calculated for companies included in the 10th decile of the stock exchanges analyzed in the 2018 Duff & Phelps Valuation Handbook as of the Valuation Date. The size premium was based on equity value before consideration of non-operating assets.
- (4) The final common component of the CAPM model is the specific company risk premium. The specific company risk quantifies the risk associated with the specific operations of the company or the "unsystematic" risk of the company. Our selection of a company specific risk premium adjusts not only for the additional risks inherent in the operations, but also accounts for the mitigating factors present in the operations. These risks are relative to the public markets from which the market equity risk premium, industry risk premium and small company risk premium were derived.
- (5) The risk-free rate is a proxy for the return available on a security that the market generally regards as free of default risk. The rate of return on a risk-free security was found by looking at the yields of United States Treasury securities. Ideally, the duration of the security used as an indication of the risk-free rate should match the horizon of the projected cash flows being discounted (which is into perpetuity in the present case). We used the available 20 Year Treasury rate as published by the Federal Reserve and sourced from Standard & Poor's Capital IQ as of March 16, 2020.
- (6) We reviewed capital structures for public companies operating in the industry, the current capital structure of the subject entity, and our experience with similar businesses in selecting the capital structure utilized in the WACC analysis. Please refer to the Beta Calculation page for additional detail.
- (7) The cost of debt utilized in the calculation of the WACC was based upon the available Moody's yield on seasoned corporate bonds, rating Baa, as published by the Federal Reserve and sourced from Standard & Poor's Capital IQ as of March 16, 2020.
- (8) To calculate the after-tax cost of debt component in the WACC formula, we utilized the blended state and federal income tax rate applicable to the state of California.



#### STANFORD HEALTH CARE ADVANTAGE Cost of Capital | Beta Calculation

	Ticke	r S&P Credit Rating	Market Capitalization	Total Debt	Minority Interest	Preferred Equity	Debt / TIC <sup>(3)</sup>	Debt / Equity	Effective Tax Rate <sup>(4)</sup>	Levered Beta <sup>(2)</sup>	Unlevered Beta <sup>(5)</sup>
1. Centene Corporation	CNO	BBB-	\$31,705,383	\$14,520,000	\$141,000	-	31.3%	45.6%	36.0%	0.921	0.713
2. Humana Inc.	HUN	1 BBB+	\$35,701,186	\$6,339,000	-	-	15.1%	17.8%	35.6%	0.972	0.872
3. Molina Healthcare, Inc.	MO	H BB-	\$7,398,752	\$1,567,000	-	-	17.5%	21.2%	40.2%	1.022	0.907
4. Anthem, Inc.	ANT	A N	\$56,531,995	\$21,076,000	-	-	27.2%	37.3%	28.0%	0.847	0.668
5. Cigna Corporation	CI	A-	\$56,044,550	\$38,038,000	\$41,000	-	40.4%	67.8%	30.6%	0.958	0.652
6. UnitedHealth Group Inco	rporated UNI	I A+	\$213,466,952	\$44,637,000	\$4,546,000	-	17.0%	20.5%	28.1%	1.018	0.887

Number of Observations	6	6	6	6	6
Low	15.1%	17.8%	28.0%	0.847	0.652
25th Percentile	17.1%	20.7%	28.7%	0.931	0.679
Median	22.3%	29.2%	33.1%	0.965	0.793
Mean	24.7%	35.0%	33.1%	0.957	0.783
75th Percentile	30.3%	43.5%	35.9%	1.006	0.883
High	40.4%	67.8%	40.2%	1.022	0.907
Standard Deviation	0.091	0.178	0.045	0.060	0.108
Coefficient of Variation	36.9%	50.7%	13.7%	6.3%	13.7%

#### **Re-Levered Beta Calculation**

Median Public Comparable Unlevered Beta	Median of the Guideline Public Company Unlevered Betas:	0.793
Target Company Debt / Equity	Based on the Industry Norm:	25.0%
Blended Federal & State Income Tax Expense	Business' Marginal Tax Rate:	28.0%
Re-Levered Beta, Subject Company <sup>(6)</sup>		0.935

#### Notes & Sources

(1) Source: Standard & Poor's Capital IQ as of March 16, 2020. Please note that United States dollars are presented in thousands.

- (2) The 5 Year levered beta was sourced from Standard & Poor's Capital IQ, and computed by taking the slope of a weekly regression line of the percentage change of the stock relative to the percentage price change in the S&P 500 as of March 16, 2020.
- (3) The Debt / TIC ratio was sourced from Standard & Poor's Capital IQ, and represents the median of the public companies' debt structure as of March 16, 2020.
- (4) A 5 Year effective tax rate was calculated to match the beta calculation period and adjust for single-period inconsistencies. A marginal tax rate was selected for the following companies (tickers) due to the calculation of a negative effective tax rate:
- (5) Unlevered Beta = Levered Beta / (1 + ((D/E) \* (1 T)) + P/E)

(6) Re-levered Beta = Unlevered Beta \*(1 + ((D/E) \* (1 - T)))



**COST APPROACH** 

#### STANFORD HEALTH CARE ADVANTAGE Cost Approach | Build-Up Approach

	Estimated Value	Stated as a % of TIC Estimated Value	Key Assumptions
Estimated Normalized Tangible Net Equity	4,418,424	100.0%	Estimated at 10.6% of Total Net Operating Revenue See Footnote 1.
Limited Scope Cost Approach Value Indication	\$4,418,424	100.0%	

#### Notes & Sources

(1) VMG assumed a normalized level of TNE at approximately 10.6% of Net Operating Revenue based on 200% of the existing required level of TNE.



MARKET APPROACH

#### Market Approach | Guideline Public Company Method

Capitalization Data	Ticker	Market Capitalization	Total Debt	Minority Interest	Preferred Equity	Cash & Short-Term Investments	Total Invested Capital
1. Centene Corporation	CNC	\$31,705,383	\$14,520,000	\$141,000	-	\$12,986,000	\$46,366,383
2. Humana Inc.	HUM	35,701,186	6,339,000	-	-	15,026,000	42,040,186
3. Molina Healthcare, Inc.	MOH	7,398,752	1,567,000	-	-	4,398,000	8,965,752
4. Anthem, Inc.	ANTM	56,531,995	21,076,000	-	-	25,635,000	77,607,995
5. Cigna Corporation	CI	56,044,550	38,038,000	41,000	-	5,556,000	94,123,550
6. UnitedHealth Group Incorporated	UNH	213,466,952	44,637,000	4,546,000	-	14,245,000	262,649,952

Financial Performance	Ticker	TTM Revenue	FY + 1 Revenue	FY + 2 Revenue	TTM EBITDA	FY + 1 EBITDA	FY + 2 EBITDA
1. Centene Corporation	CNC	\$70,791,000	\$105,350,387	\$113,855,872	\$3,410,000	\$5,126,321	\$5,352,985
2. Humana Inc.	HUM	64,888,000	74,055,823	81,103,270	3,676,000	4,195,586	4,530,914
3. Molina Healthcare, Inc.	МОН	16,340,000	18,401,245	18,836,622	1,140,000	1,169,032	1,175,149
4. Anthem, Inc.	ANTM	104,212,000	117,559,708	127,047,541	7,523,000	9,072,728	9,733,593
5. Cigna Corporation	CI	153,743,000	154,040,923	163,342,859	12,051,000	11,587,964	12,010,704
6. UnitedHealth Group Incorporated	UNH	242,155,000	261,714,115	282,294,489	22,684,000	24,981,320	27,269,428

Valuation Multiples	Ticker	TTM Revenue	FY + 1 Revenue	FY + 2 Revenue	TTM EBITDA	FY + 1 EBITDA	FY + 2 EBITDA
1. Centene Corporation	CNC	0.7x	0.4x	0.4x	13.6x	9.0x	8.7x
2. Humana Inc.	HUM	0.6x	0.6x	0.5x	11.4x	10.0x	9.3x
3. Molina Healthcare, Inc.	MOH	0.5x	0.5x	0.5x	7.9x	7.7x	7.6x
4. Anthem, Inc.	ANTM	0.7x	0.7x	0.6x	10.3x	8.6x	8.0x
5. Cigna Corporation	CI	0.6x	0.6x	0.6x	7.8x	8.1x	7.8x
6. UnitedHealth Group Incorporated	UNH	1.1x	1.0x	0.9x	11.6x	10.5x	9.6x

Low	0.5x	0.4x	0.4x	7.8x	7.7x	7.6x
25th Percentile	0.6x	0.5x	0.5x	8.5x	8.2x	7.9x
Median	0.7x	0.6x	0.5x	10.9x	8.8x	8.3x
Mean	0.7x	0.6x	0.6x	10.4x	9.0x	8.5x
75th Percentile	0.7x	0.6x	0.6x	11.5x	9.8x	9.1x
High	1.1x	1.0x	0.9x	13.6x	10.5x	9.6x

#### Notes & Sources

(1) Sources: Standard & Poor's Capital IQ as of March 16, 2020.

(2) Total Invested Capital ("TIC") is defined as Market Value of Equity plus Interest-bearing Debt.



#### Market Approach | Guideline Public Company Analysis

Revenue Growth	CNC	HUM	МОН	ANTM	CI	UNH	Mean	Median	Subject Business	EBITDA Growth	CNC	HUM	МОН	ANTM	CI	UNH	Mean	Median	Subject Business
FYE - 2	21.5%	(1.1%)	14.2%	6.1%	5.1%	8.8%	9.1%	7.5%	n/a	FYE - 2	(3.3%)	78.7%	(42.0%)	(5.4%)	29.2%	16.5%	12.3%	6.6%	n/a
FYE - 1	23.7%	5.8%	(6.7%)	2.3%	15.5%	12.5%	8.9%	9.2%	67.6%	FYE - 1	43.9%	(9.2%)	462.6%	19.4%	12.9%	13.4%	90.5%	16.4%	n/a
FYE	24.9%	14.0%	(9.9%)	13.2%	216.5%	7.0%	44.3%	13.6%	45.3%	FYE	22.1%	4.0%	(11.4%)	14.6%	126.0%	13.1%	28.1%	13.9%	n/a
Year 1	48.8%	14.1%	12.6%	12.8%	0.2%	8.1%	16.1%	12.7%	23.6%	Year 1	59.8%	20.9%	5.7%	24.4%	(1.9%)	15.2%	20.7%	18.0%	n/a
Year 2	8.1%	9.5%	2.4%	8.1%	6.0%	7.9%	7.0%	8.0%	23.7%	Year 2	4.4%	8.0%	0.5%	7.3%	3.6%	9.2%	5.5%	5.9%	n/a
Year 3	7.0%	8.7%	8.4%	8.3%	6.4%	6.5%	7.6%	7.7%	23.7%	Year 3	5.4%	10.6%	6.5%	n/a	2.4%	10.2%	7.0%	6.5%	n/a

EBITDA Margin	CNC	ним	МОН	ANTM	CI	UNH	Mean	Median	Subject Business	Capital Expenditures	CNC	HUM	МОН	ANTM	CI	UNH	Mean	Ivledian	Subject Business
FYE - 2	4.0%	6.8%	1.1%	5.9%	11.0%	8.4%	6.2%	6.4%	(64.9%)	FYE - 3	0.8%	1.0%	1.0%	0.7%	1.2%	0.9%	0.9%	0.9%	n/a
FYE - 1	4.6%	5.9%	6.9%	6.9%	10.8%	8.5%	7.3%	6.9%	(46.4%)	FYE - 2	0.9%	1.0%	0.4%	0.9%	1.1%	1.0%	0.9%	0.9%	n/a
FYE	4.5%	5.3%	6.8%	7.0%	7.7%	9.0%	6.7%	6.9%	(22.8%)	FYE - 1	1.2%	1.1%	0.2%	1.3%	1.1%	0.9%	1.0%	1.1%	n/a
TTM	4.5%	5.3%	6.8%	7.0%	7.7%	9.0%	6.7%	6.9%	(22.8%)	FYE	1.0%	1.1%	0.3%	1.0%	0.7%	0.9%	0.8%	0.9%	n/a
Year 1	4.9%	5.7%	6.4%	7.7%	7.5%	9.5%	6.9%	6.9%	(19.6%)	TTM	1.0%	1.1%	0.3%	1.0%	0.7%	0.9%	0.8%	0.9%	n/a
Year 2	4.7%	5.6%	6.2%	7.7%	7.4%	9.7%	6.9%	6.8%	(16.5%)										
Year 3	4.6%	5.7%	6.1%	n/a	7.1%	10.0%	6.7%	6.1%	(13.3%)										

Net Working Capital	CNC	HUM	МОН	ANTM	CI	UNH	Mean	Median	Subject Business	Cash-Free NWC	CNC	HUM	МОН	ANTM	CI	UNH	Mean	Median	Subject Business
FYE - 3	0.7%	30.3%	21.4%	40.2%	4.1%	(4.6%)	15.4%	12.8%	n/a	FYE - 3	(11.1%)	9.2%	(5.5%)	13.4%	(5.5%)	(11.7%)	(1.9%)	(5.5%)	n/a
FYE - 2	(0.2%)	33.2%	26.4%	41.0%	1.5%	(5.0%)	16.1%	14.0%	12.1%	FYE - 2	(10.3%)	7.9%	(3.0%)	13.7%	(10.6%)	(12.7%)	(2.5%)	(6.6%)	(34.1%)
FYE - 1	1.4%	33.0%	22.8%	36.0%	(13.4%)	(5.4%)	12.4%	12.1%	13.5%	FYE - 1	(9.3%)	11.2%	(2.0%)	12.0%	(25.5%)	(11.7%)	(4.2%)	(5.7%)	(35.0%)
FYE	12.0%	32.3%	28.7%	37.3%	(2.4%)	(5.9%)	17.0%	20.4%	11.8%	FYE	(6.3%)	9.2%	1.8%	12.7%	(6.0%)	(11.8%)	(0.1%)	(2.1%)	(16.7%)
TTM	12.0%	32.3%	28.7%	37.3%	(2.4%)	(5.9%)	17.0%	20.4%	11.8%	TTM	(6.3%)	9.2%	1.8%	12.7%	(6.0%)	(11.8%)	(0.1%)	(2.1%)	(16.7%)

Capital Structure	CNC	HUM	МОН	ANTM	CI	UNH	Mean	Median	Subject Business	Additional Data	CNC	HUM	мон	ANTM	CI	UNH	Mean	Median	Subject Business
FYE - 3	32.5%	12.4%	34.8%	30.7%	12.8%	17.6%	23.5%	24.2%	n/a	SW&B	n/a	n/a							
FYE - 2	21.5%	12.8%	33.1%	26.1%	9.8%	12.7%	19.3%	17.1%	n/a	Supplies	n/a	n/a							
FYE - 1	22.1%	13.7%	16.7%	22.6%	37.0%	13.0%	20.9%	19.4%	n/a	COGS	83.1%	83.0%	85.1%	78.5%	83.6%	76.2%	81.6%	83.1%	100.6%
FYE	35.7%	11.6%	15.6%	21.6%	33.2%	13.6%	21.9%	18.6%	n/a	SG&A	9.1%	11.3%	7.9%	14.7%	8.6%	14.5%	11.0%	10.2%	22.2%
TTM	31.3%	15.1%	17.5%	27.2%	40.4%	17.0%	24.7%	22.3%	n/a	D&A	0.4%	0.7%	0.5%	0.3%	1.9%	1.1%	0.8%	0.6%	n/a


#### Notes & Sources

(1) Sources: Standard & Poor's Capital IQ as of March 16, 2020.



Final Report

#### Market Approach | Public Guideline Company Comparables



Aetna	Anthem	Cigna	UnitedHealth	Centene	Humana	Molina
3,591,000 10,594,000 -	3,920,000 11,945,000 18,482,000	2,379,000 1,096,000 1,597,000	8,575,000 20,075,000 5,720,000	2,331,100 9,043,200 779,800	1,207,000 14,931,000 5,147,000	- 3,331,000 -
, ,	, ,				808,100	- 3,331,000
	3,591,000 10,594,000	3,591,000 3,920,000 10,594,000 11,945,000 - 18,482,000 14,717,000 30,934,000	3,591,000 3,920,000 2,379,000 10,594,000 11,945,000 1,096,000 - 18,482,000 1,597,000 14,717,000 30,934,000 12,073,000	3,591,0003,920,0002,379,0008,575,00010,594,00011,945,0001,096,00020,075,000-18,482,0001,597,0005,720,00014,717,00030,934,00012,073,00019,185,000	3,591,000         3,920,000         2,379,000         8,575,000         2,331,100           10,594,000         11,945,000         1,096,000         20,075,000         9,043,200           -         18,482,000         1,597,000         5,720,000         779,800           14,717,000         30,934,000         12,073,000         19,185,000         3,087,700	3,591,000         3,920,000         2,379,000         8,575,000         2,331,100         1,207,000           10,594,000         11,945,000         1,096,000         20,075,000         9,043,200         14,931,000           -         18,482,000         1,597,000         5,720,000         779,800         5,147,000           14,717,000         30,934,000         12,073,000         19,185,000         3,087,700         808,100

#### Notes & Sources


(1) Source: S&P Capital IQ

(2) Please note, individual public guideline companies do not report membership statistics uniformly.



#### Market Approach | Public Guideline Company Comparables

## Public Managed Care Medical Loss Ratios



2017 2018 2019

#### Notes & Sources

(1) Source: S&P Capital IQ



Final Report

#### Market Approach | Public Guideline Company Comparables

#### Public Managed Care Administrative Cost Ratios



2017 2018 2019

#### Notes & Sources

(1) Source: S&P Capital IQ



#### STANFORD HEALTH CARE ADVANTAGE Market Approach | GPC Detailed Descriptions

CNC Centene Corporation operates as a multi-national healthcare enterprise that provides programs and services to under-insured and uninsured individuals in the United States. Its Managed Care segment offers health plan coverage to individuals through government subsidized programs, including Medicaid, the State children's health insurance program, long-term services and support, foster care, and medicare-medicaid plans, which cover dually eligible individuals, as well as aged, blind, or disabled programs. Its health plans include primary and specialty physician care, inpatient and outpatient hospital care, emergency and urgent care, prenatal care, laboratory and X-ray, home-based primary care, transportation assistance, vision care, dental care, telehealth, immunization, specialty pharmacy, therapy, social work, nurse advisory, and care coordination services, as well as prescriptions and limited over-the-counter drugs, medical equipment, and behavioral health and abuse services. This segment also offers various individual, small group, and large group commercial healthcare products to employers and directly to members in the Managed Care segment. The company's Specialty Services segment provides pharmacy benefits management services; health, triage, wellness, and disease management services; and vision and dental, and management services, as well as care management software that automate the clinical, administrative, and technical components of care management programs; staffing services; and services to Military Health System eligible beneficiaries. This segment offers its services and products to state programs, correctional facilities, healthcare organizations, employer groups, and other commercial organizations. The company provides its services through primary and specialty care physicians, hospitals, and ancillary providers. Centene Corporation was founded in 1984 and is headquartered in St. Louis, Missouri.

- HUM Humana Inc., together with its subsidiaries, operates as a health and well-being company in the United States. It operates through Retail, Group and Specialty, and Healthcare Services segments. The company offers medical and supplemental benefit plans to individuals. It also has contract with Centers for Medicare and Medicaid Services to administer the Limited Income Newly Eligible Transition prescription drug plan program; and contracts with various states to provide Medicaid, dual eligible, and long-term support services benefits. In addition, the company provides commercial fully-insured medical and specialty health insurance benefits comprising dental, vision, and other supplemental health benefits; financial protection products; and administrative services only products to individuals and employer groups, as well as military services, such as TRICARE South Region contract. Further, it offers pharmacy solutions, provider services, predictive modeling and informatics services, and clinical care services, such as home health and other services to its health plan members, as well as to third parties. As of December 31, 2019, the company had approximately 17 million members in medical benefit plans, as well as approximately 5 million members in specialty products. Humana Inc. was founded in 1961 and is headquartered in Louisville, Kentucky.
- MOH Molina Healthcare, Inc. provides managed health care services to low-income families and individuals under the Medicaid and Medicare programs and through the state insurance marketplaces. The company operates in two segments, Health Plans and Other. As of December 31, 2019, it served approximately 3.3 million members in 14 states and the Commonwealth of Puerto Rico, who are eligible for Medicaid, Medicare, and other government-sponsored health care programs. The company offers its health care services for its members through contracts with a network of providers, including independent physicians and physician groups, hospitals, ancillary providers, and pharmacies. Molina Healthcare, Inc. was founded in 1980 and is headquartered in Long Beach, California.

ANTM Anthem, Inc., through its subsidiaries, operates as a health benefits company in the United States. It operates through three segments: Commercial & Specialty Business, Government Business, and Other. The company offers a spectrum of network-based managed care health benefit plans to large and small group, individual, Medicaid, and Medicare markets. Its managed care plans include preferred provider organizations; health maintenance organizations; point-of-service plans; traditional indemnity plans and other hybrid plans, such as consumer-driven health plans; and hospital only and limited benefit products. The company also provides a range of managed care services to selffunded customers, including claims processing, underwriting, stop loss insurance, actuarial services, provider network access, medical cost management, disease management, wellness programs, and other administrative services. In addition, it offers an array of specialty and other insurance products and services, such as dental, vision, life and disability insurance benefits, radiology benefit management, and analytics-driven personal health care guidance; and Medicare administrative services. Further, the company provides services to the federal government in connection with the Federal Employee Program; and operates as a licensee of the Blue Cross and Blue Shield Association. As of December 31, 2019, it served 41 million medical members through its affiliated health plans. The company was formerly known as WellPoint, Inc. and changed its name to Anthem, Inc. in December 2014. Anthem, Inc. was founded in 1944 and is headquartered in Indianapolis, Indiana.



#### STANFORD HEALTH CARE ADVANTAGE Market Approach | GPC Detailed Descriptions

CI Cigna Corporation, a health service organization, provides insurance and related products and services in the United States and internationally. It operates through Integrated Medical, Health Services, International Markets, and Group Disability and Other segments. The Integrated Medical segment offers medical, pharmacy, dental, behavioral health and vision, health advocacy programs, and other products and services to insured and self-insured clients; Medicare Advantage, Medicare Supplement, and Medicare Part D plans to Medicare-eligible beneficiaries, as well as Medicaid plans; and health insurance coverage to individual customers on and off the public exchanges. The Health Services segment provides clinical solutions, specialized pharmacy care, home delivery pharmacy, retail network pharmacy administration, benefit design consultation, drug utilization review, drug formulary management drug claim adjudication, digital consumer health and drug information, provider, and medical benefits to mobile employees of multinational organizations. This segment offers health coverage, hospitalization, dental, critical illness, personal accident, term life, and variable universal life products. The Group Disability and Other segment provides group long-term and short-term disability, group life, accident, and voluntary and specialty insurance products and related services; and permanent insurance contracts to corporations to provide coverage on the lives of certain employees for the purpose of financing employer-paid future benefit obligations. The company distributes its products and services through insurance brokers and insurance consultants; and directly to employers, unions and other groups, or individuals. Cigna Corporation was founded in 1792 and is headquartered in Bloomfield, Connecticut.

UNH UnitedHealth Group Incorporated operates as a diversified health care company in the United States. It operates through four segments: UnitedHealthcare, OptumHealth, OptumInsight, and OptumRx. The UnitedHealthcare segment offers consumer-oriented health benefit plans and services for national employers, public sector employers, midsized employers, small businesses, and individuals; health and well-being services to individuals age 50 and older, addressing their needs for preventive and acute health care services, as well as services dealing with chronic disease and other specialized issues for older individuals; Medicaid plans, Children's Health Insurance Program, and health care programs; medical and dental benefits; and health care delivery. The OptumHealth segment provides access to networks of care provider specialists, health management services, care delivery, consumer engagement, and financial services. This segment serves individuals through programs offered by employers, payers, government entities, and directly with the care delivery systems. The OptumInsight segment offers software and information products, advisory consulting arrangements, and services outsourcing contracts to hospital systems, physicians, health plans, governments, life sciences companies, and other organizations. The OptumRx segment provides pharmacy care services and programs, including retail network contracting, home delivery, specialty and compounding pharmacy, and purchasing and clinical, as well as develops programs in areas, such as step therapy, formulary management, drug adherence, and disease/drug therapy management. UnitedHealth Group Incorporated was founded in 1974 and is based in Minnetonka, Minnesota.

#### Notes & Sources

(1) Sources: Standard & Poor's Capital IQ as of March 16, 2020.



#### Market Approach | M&A Multiples

VMG Medicare Advantage Database (1)	TIC / Revenue	TIC / EBITDA	TIC / Membership
25th Percentile	0.4x	8.0x	\$2,217
Median	0.5x	11.3x	\$3,478
Mean	0.7x	12.7x	\$4,947
75th Percentile	0.9x	13.6x	\$6,353

#### Notes & Sources

(1) Sources: S&P Capital IQ, Irving Levin Associates, and company specific SEC filings.



**SUPPLEMENTAL ANALYSES** -SCENARIO VALUE CALCULATION

#### **Overview - Scenario Value Calculation**

Per the request of Stanford Health Care management, an alternative value calculation was performed which includes the following assumptions:

(1) Assume the Business invests \$10.0 million in technology which results in an immediate administrative cost structure at 15.0% of net operating revenue which results in immediate savings relative to base case; and
(2) All other assumptions were held constant.

#### Supplemental Analysis - Undiscounted Net Discretionary Cash Flow Variance

Base Case		Year 1	Year 2	Year 3	Year 4	Year 5
Undiscounted Net Discretionary Cash Flow	(a)	(11,127,301)	(11,758,499)	(12,067,964)	(11,865,015)	(10,886,202)
Cumulative Undiscounted Net Discretionary Cash Flow		(57,704,982)				
Alternative Value Scenario		Year 1	Year 2	Year 3	Year 4	Year 5
Undiscounted Net Discretionary Cash Flow	(b)	(17,956,523)	(8,499,666)	(8,856,171)	(8,905,237)	(8,478,982)
Cumulative Undiscounted Net Discretionary Cash Flow		(52,696,579)				
Variance		Year 1	Year 2	Year 3	Year 4	Year 5
Undiscounted Net Discretionary Cash Flow Variance	(b) - (a)	(6,829,222)	3,258,833	3,211,794	2,959,779	2,407,220
Cumulative Undiscounted Net Discretionary Cash Flow Vari	ance	5,008,403				

#### Conclusion

While the net discretionary cash flow in the alternative value scenario is improved from the base case scenario, the alternative net discretionary cash flow is still negative and does not result in a positive value indication.



#### Scenario Value Calculation | Revenue Assumptions

Attribute Municher Marching Growells         22,714         55,517         66,572         81,577         90,709         120,000         Attender methoder Marching         Attender Municher Marching         Attender Municher Marching         Attender Municher Marching         Attender Municher Munich         57,070         91,270         91,270         91,200         Attender Municher Munich         57,071         52,187         22,38							F	Projection Period	1		
Attribute Municher Marching Growells         22,714         55,517         66,572         81,577         90,709         120,000         Attender methoder Marching         Attender Municher Marching         Attender Municher Marching         Attender Municher Marching         Attender Municher Munich         57,070         91,270         91,270         91,200         Attender Municher Munich         57,071         52,187         22,38		CY 2017	CY 2018	CY 2019	NBY	Year 1	Year 2	Year 3	Year 4	Year 5	Key Assumptions
Growth       v/o       51.05       31.05       -       21.05       21.0	Revenue										
Name         Name <th< td=""><td>Estimated Member Months</td><td>22,714</td><td>34,501</td><td>45,375</td><td>45,375</td><td>55,117</td><td>66,952</td><td>81,327</td><td>98,789</td><td>120,000</td><td>Assumed membership increases to 10,000 cover</td></th<>	Estimated Member Months	22,714	34,501	45,375	45,375	55,117	66,952	81,327	98,789	120,000	Assumed membership increases to 10,000 cover
Growth         N/h         1.23         9.24         -         2.05         2.07         2.08         2.07         2.09         2	Growth	n/a	51.9%	31.5%	-	21.5%	21.5%	21.5%	21.5%	21.5%	lives by Yr. 5
Interface Advantage Net Prenum Revenue         \$17,057,871         \$28,585,55         \$41,02,021,07         \$40,030,01         \$40,250         \$	verage Net Revenue per Member Month				\$904.97						
print         442,500	Growth	n/a	10.3%	9.2%	-	2.0%	2.0%	2.0%	2.0%	2.0%	
Alt Operating Revenue Growth         Str 0.57.371         Str 2.58.65.27         Str 3.39.627         Str 3.39.627         Str 2.57.68         Str 2.27.68         Str 2.37.68         Str 2.37.68 <th< td=""><td>ledicare Advantage Net Premium Revenue</td><td>\$17,057,871</td><td>\$28,586,553</td><td>\$41,062,917</td><td>\$41,062,917</td><td>\$50,877,127</td><td>\$63,036,974</td><td>\$78,103,075</td><td>\$96,770,038</td><td>\$119,898,483</td><td></td></th<>	ledicare Advantage Net Premium Revenue	\$17,057,871	\$28,586,553	\$41,062,917	\$41,062,917	\$50,877,127	\$63,036,974	\$78,103,075	\$96,770,038	\$119,898,483	
Growth         n/φ         67.6%         45.3%         -         22.6%         23.7%         23.8%         23.	ptional Supplemental Benefits		-	462,500	462,500	462,500	462,500	462,500	462,500	462,500	No Growth
Addcal Expenses         S5,444,725         \$2,543,53,55         \$12,246,860         \$12,256,850         \$12,256,850         \$12,256,850         \$12,256,850         \$12,266,850					\$41,525,417						
aptistion         \$5,44,735         \$8,153,158         \$12,321,846         \$12,321,846         \$12,321,846         \$12,321,846         \$12,321,846         \$12,321,846         \$12,321,846         \$12,321,846         \$12,321,846,880         \$12,851,88         \$13,851,88         \$12,851,88         \$12,851,88         \$12,851,88         \$12,851,88         \$12,851,88         \$12,851,88         \$12,851,88         \$12,852,88	Growth	n/a	67.6%	45.3%	-	23.6%	23.7%	23.7%	23.8%	23.8%	
patient SNF Claims         7,805,95         12,664,82         12,646,820         7,845,820         9,245,820         9,218         9,0004         9,845,820         9,218         9,0004         9,845,820         9,218         9,218         9,218         9,218         9,004         9,118,118,113,110,110,110,110,110,110,110,110,110	Medical Expenses										
unput stant         4,513,13         8,755,28         9,475,523         9,475,523         management and care coordination of photomic states with health care providers.           ut of Network Claims         1,995,852         2,533,981         1,995,852         2,533,981         1,995,852         2,533,981         1,995,852         2,533,981         1,995,852         2,533,981         1,995,852         2,533,981         1,995,852         2,533,981         1,995,852         2,533,981         1,995,852         2,533,981         1,995,852         2,533,981         1,995,852         2,533,881         1,965,156         550,550,946         561,180,376         574,033,833         589,556,675         5108,324,485         - <t< td=""><td>apitation</td><td>\$5,444,735</td><td>\$8,153,158</td><td>\$12,321,846</td><td>\$12,321,846</td><td></td><td></td><td></td><td></td><td></td><td>Management represented that Year 5 MLR o</td></t<>	apitation	\$5,444,735	\$8,153,158	\$12,321,846	\$12,321,846						Management represented that Year 5 MLR o
int of Neurolic Claims       1.995,853       2,523,591       3,195,115       3,195,115       Projected expenses reflect exstance contract.         immare Claims - Part B       225,349       8(80),846       (80),9	patient & SNF Claims	7,806,985	12,666,482	12,546,880	12,546,880						90.0% is achievable with increased care
Calibration Common C	utpatient & Professional Claims	4,513,113	8,759,548	9,475,525	9,475,525						
all in Reductions of Recovering Signal Part B         199,949 (10,192,2)         100,192,20,2)         100,192,20,2)         100,192,20,20,2)         100,192,20,20,2)         100,192,20,20,2)         100,192,20,10,2,20,0)         100,192,20,10,2,20,0)         100,192,20,10,2,20,0)         100,192,20,10,2,20,0)         100,192,20,10,2,20,0,2,20,1,2,20,1,2,20,10,2,20,0)         100,192,20,10,2,20,0,2,20,1,2,20,10,2,20,0,2,20,1,2,20,1,2,20,0,2,20,1,2,20,0,2,20,1,2,20,0,2,20,1,2,20,0,2,20,1,2,20,0,2,20,1,2,20,0,2,20,1,2,20,0,2,20,0,2,20,1,2,20,0,2,20,0,2,20,0,2,20,0,2,20,0,2,20,0,2,20,0,2,20,0,2,20,0,2,20,0,2,20,0,2,20,0,2,20,0,2,20,0,2,20,0,2,20,0,2,	ut of Network Claims	1,995,852	2,523,691	3,196,116	3,196,116						
hammacy Calmis - Part D       2.108,854       2.907,365       3.828,366       3.828,366       3.828,366       3.828,366       3.828,366       3.828,366       3.828,366       3.828,366       3.828,366       3.828,366       3.828,366       3.828,366       5.82,792       653,838       98,556,675       5108,324,885       74       <	aim Refunds & Recoveries	(99,849)	(801,872)	(809,846)	(809,846)						rates with health care providers.
nammacy (James - Yari D         2,108,284         2,207,385         3,282,366         3,282,366	harmacy Claims - Part B	235,498	229,716	554,480	554,480						The improvement in MLR is forecasted linear
piptional Supplemental Benefits Expense         -	harmacy Claims - Part D	2,108,854	2,907,365	3,828,366	3,828,366						
Image: constraint of MLR*)         129.0%         120.5%         100.6%         98.5%         96.3%         94.2%         92.1%         90.0%         Per Management           Growth         n/a         (6.6%)         (16.5%)         n/a         (2.1%)         (2.2%)         (2.2%)         (2.2%)         (2.2%)         (2.2%)         (2.2%)         (2.3%)         Per Management	ptional Supplemental Benefits Expense		-	,	,	650 550 046	¢c1 100 270	674 022 022	600 FCC C7F	¢100.224.005	
Growth       n/a       (6.6%)       (16.5%)       n/a       (2.1%)       (2.1%)       (2.2%)		\$22,005,188	ŞS4,4S0,000	\$41,700,159	\$41,700,159	ŞSU,SSU,940	\$01,180,576	\$74,055,655	\$69,500,075	\$100,524,005	×
Administrative Expenses       S2,653,492       S3,172,432       S2,760,312       S2,760,312       S2,760,312       Management represented that a \$10.0 million capital spend to upgrade administrative (Care Counsel)       Management represented that a \$10.0 million capital spend to upgrade administrative (Care Counsel)       Management represented that a \$10.0 million capital spend to upgrade administrative (Care Counsel)       Management represented that a \$10.0 million capital spend to upgrade administrative (Care Counsel)       Management represented that a \$10.0 million capital spend to upgrade administrative (Care Counsel)       Management represented that a \$10.0 million capital spend to upgrade administrative (Care Counsel)       Management represented that a \$10.0 million capital spend to upgrade administrative (Care Counsel)       Management represented that a \$10.0 million capital spend to upgrade administrative (Care Counsel)         ViPro       390,400       346,220       616,050       616,050       616,050       616,050         Capanoy Expense       264,768       320,546       335,010       228,201       228,201       228,201       228,201       228,201       51,700,944       \$9,524,921       \$11,784,836       \$14,584,881       \$18,054,148       61,950       65,119,598       \$7,414,640       \$9,226,991       \$9,226,991       \$9,700,944       \$9,524,921       \$11,784,836       \$14,584,881       \$18,054,148       Management Scenario         dministrative Cost Ratio ("ACR")       35,956       25,956	ledical Loss Ratio ("MLR")	129.0%	120.5%	100.6%	100.6%	98.5%	96.3%	94.2%	92.1%	90.0%	Per Management
alarles, Wages, and Benefits       \$2,653,492       \$3,172,432       \$2,760,312       \$2,770,914       \$2,760,312       \$2,770,914       \$2,777,770,914       \$2,777       \$2,770,914       \$2,92,727       \$1,013,727       \$2,014,723,83	Growth	n/a	(6.6%)	(16.5%)	n/a	(2.1%)	(2.1%)	(2.2%)	(2.2%)	(2.3%)	
ustomer Service (Care Counsel)       465,707       377,910       691,606       691,606       691,606       691,606       691,606       691,606       for control status       copital spend to upgrade administrative infrustruture is necessary in order to achieve projected improvement in MLR.         Vibro       390,400       346,220       616,050       616,050       616,050       616,050       616,050       616,050       616,050       616,050       616,050       616,050       616,050       616,050       616,050       616,050       616,050       65,255	dministrative Expenses										
increased Services (Clinical, Rx, Admin, Misc)       792,859       534,462       1,331,317       1,331,317       1,331,317       infirustructure is necessary in order to achieve projected improvement in MLR.         pommissions       796,693       1,256,615       1,935,953       1,935,953       1,935,953       infirustructure is necessary in order to achieve projected improvement in MLR.         pommissions       796,693       1,256,615       1,037,777       1,013,727       infirustructure is necessary in order to achieve projected improvement in MLR.         inferstructure is necessary in order to achieve projected improvement in MLR.       335,010       228,201       218,054,168       \$18,054,168       \$18,054,168       \$18,054,168       \$18,054,168       \$18,054,168       \$18,054,168       \$18,054,168       \$16,069       \$16,069       \$16,069       \$16,069       \$16,069       \$16,069       \$16,069       \$16,069       \$16,069       \$16,069       \$16,069	alaries, Wages, and Benefits	\$2,653,492	\$3,172,432	\$2,760,312	\$2,760,312						Management represented that a \$10.0 millio
and activities of miles (and miles) (and miles)       1000001       10000000       1000000       1000000       1000000       1000000       1000000       10000000       10000000       10000000       100000000       1000000000       1000000000       1000000000       100000000000       10000000000       100000000000000000       1000000000000000000000000000000000000	ustomer Service (Care Counsel)	465,707	377,910	691,606	691,606						capital spend to upgrade administrative
Animstants       1,50,013       <	urchased Services (Clinical, Rx, Admin, Misc)	792,859	534,462	1,331,317	1,331,317						
rofessional Fees       256,440       889,572       1,013,727       1,014,728       1,014,728       1,11,784,836       1,14,584,881       18,054,148       1,15,064       1,1064		,			1,935,953						projected improvement in MLR.
Marketing & Outreach       320,546       335,010       228,201       201,187       291,187       291,187       291,187       291,187       291,187       291,187       291,187       293,383       293,383       293,383       293,383       293,383       293,383       293,383       293,383       293,383       293,269,991       \$7,700,944       \$9,524,921       \$11,784,836       \$14,584,881       \$18,054,148       4       4       4       4       4       4       4       4       4       4       4       5       5       5       5       5       4       4       4       4       4       4       4       5       5       5       5       6       5       5       6       5       6       5       6       5       6       5       6       5       6       5       6       5       6       6       6       6       6       6       6 </td <td>/iPro</td> <td></td>	/iPro										
ccupacy Expense       70,638       75,755       65,2		,	,								
surance       264,768       220,472       291,187       291,383       293,383       1	-										
108,055       206,182       293,383       293,283       293,283       \$11,784,836       \$14,584,881       \$18,054,148       193,054,148<											
\$6,119,598       \$7,414,640       \$9,226,991       \$7,700,944       \$9,524,921       \$11,784,836       \$14,584,881       \$18,054,148         dministrative Cost Ratio ("ACR")       35.9%       22.2%       22.2%       15.0%       15.0%       15.0%       15.0%       Normalized per Management Scenario         Growth       n/a       (27.7%)       (14.3%)       -       (32.5%)       -       -       -       -         BITDA       (\$11,066,915)       (\$13,266,175)       (\$9,467,733)       (\$9,467,733)       (\$7,205,824)       (\$7,253,094)       (\$6,919,018)       (\$6,018,049)											
Growth       n/a       (27.7%)       (14.3%)       (32.5%)       -       -       -         BITDA       (\$11,066,915)       (\$13,266,175)       (\$9,467,733)       (\$6,912,263)       (\$7,205,824)       (\$7,253,094)       (\$6,018,049)	ther		,	,	,	\$7,700,944	\$9,524,921	\$11,784,836	\$14,584,881	\$18,054,148	
Growth       n/a       (27.7%)       (14.3%)       (32.5%)       -       -       -         BITDA       (\$11,066,915)       (\$13,266,175)       (\$9,467,733)       (\$6,912,263)       (\$7,205,824)       (\$7,253,094)       (\$6,018,049)	dministrative Cost Ratio ("ACR")	35.9%	25.9%	22.2%	22. <u>2%</u>	15.0%	15.0%	15.0%	15.0%	15.0%	Normalized per Management Scenario
					-		-	-	-	-	
BITDA Margin (64.9%) (46.4%) (22.8%) (22.8%) (13.5%) (11.3%) (9.2%) (7.1%) (5.0%)	EBITDA	(\$11,066,915)	(\$13,266,175)	(\$9,467,733)	(\$9,467,733)	(\$6,912,263)	(\$7,205,824)	(\$7,253,094)	(\$6,919,018)	(\$6,018,049)	
	EBITDA Margin	(64.9%)	(46.4%)	(22.8%)	(22.8%)	(13.5%)	(11.3%)	(9.2%)	(7.1%)	(5.0%)	



#### Scenario Value Calculation | Discounted Cash Flow Assumptions

#### **Discounted Cash Flow Analysis Assumptions**

Discount Rate	15.0%
Normalized Net Working Capital	\$4,418,424
<ul> <li>Normalized Net Working Capital as a Percentage of Total Net Operating Revenue</li> </ul>	10.6%
<ul> <li>Selected Incremental Net Working Capital Requirements as a Percentage of Total Net Operating Revenue</li> </ul>	10.6%
<ul> <li>Inflation Rate</li> </ul>	3.0%
Terminal Growth Rate	2.0%
Tax Rate	28.0%
Depreciation Assumptions	

Net Initial Depreciable Basis of Furniture, Fixtures, Equipment & Leasehold Improvements	
<ul> <li>Estimated Useful Life of Initial Furniture, Fixtures, Equipment &amp; Leasehold Improvements</li> </ul>	7.0
<ul> <li>Estimated Useful Life of Projected Furniture, Fixtures, Equipment &amp; Leasehold Improvement Expenditures</li> </ul>	10.0

Projected Capital Expenditures & Depreciation Expense <sup>(1), (2)</sup>	Year 1	Year 2	Year 3	Year 4	Year 5	Terminal Year
Capital Expenditures & Improvements						
Furniture, Fixtures, Equipment & Leasehold Improvements <sup>(1)</sup>	\$10,000,000	-	-	-	-	-
Real Estate	-	-	-	-	-	-
Total Capital Expenditures	\$10,000,000	-	-	-	-	-
As a Percentage of Total Net Operating Revenue	19.5%	-	-	-	-	-
Depreciation Schedule						
Depreciation of Initial Net Fixed Assets	-	-	-	-	-	
Calculated Depreciation of Capital Expenditures	10,000,000	-	-	-	-	
Total Depreciation	\$10,000,000	-	-	-	-	-

#### Notes & Sources

- (1) No discrete routine capital is projected as it is assumed to be captured in the administrative cost ratio charge; however, \$10.0 million capital expenditures in Year 1 reflect upgrades to the administrative functions of the Business such that the Administrative Cost Ratio is normalized at 15.0% of Net Operating Revenue throughout the projection period.
- (2) Projected Depreciation & Amortization expense was based on the Tax Cut and Jobs Act signed into law on December 22, 2017. Depreciation was modeled assuming a hypothetical control transaction using an asset deal structure. A hypothetical buyers is assumed to take full advantage of this new law and, therefore, depreciation expense in Year One includes the full expensing of acquired net fixed assets plus the full expensing of any capital expenditures. Depreciation in Year 2 through Year 5 assumes full expensing for all assets with tax lives of 15.0 years or less, including qualified leasehold improvements. Please note, this bonus depreciation is subject to phase-out in the future.



#### STANFORD HEALTH CARE ADVANTAGE Scenario Value Calculation | Cash Flow Projections

						Projection Period					
	CY 2017	CY 2018	CY 2019	CY 2019	NBY	Year 1	Year 2	Year 3	Year 4	Year 5	Terminal Year
Revenues											
Premium Revenue	\$17,057,871	\$28,586,553	\$41,062,917	\$41,062,917	\$41,062,917	\$50,877,127	\$63,036,974	\$78,103,075	\$96,770,038	\$119,898,483	
Optional Supplemental Benefits	-	-	462,500	462,500	462,500	462,500	462,500	462,500	462,500	462,500	
Total Net Operating Revenue	17,057,871	28,586,553	41,525,417	41,525,417	41,525,417	51,339,627	63,499,474	78,565,575	97,232,538	120,360,983	122,768,203
Growth	n/a	67.6%	45.3%	-	-	23.6%	23.7%	23.7%	23.8%	23.8%	2.0%
Operating Expenses											
Medical Expense	22,005,188	34,438,088	41,766,159	41,766,159	41,766,159	50,550,946	61,180,376	74,033,833	89,566,675	108,324,885	
General & Administrative	6,119,598	7,414,640	9,226,991	9,226,991	9,226,991	7,700,944	9,524,921	11,784,836	14,584,881	18,054,148	
Total Operating Expenses	28,124,786	41,852,728	50,993,150	50,993,150	50,993,150	58,251,890	70,705,297	85,818,669	104,151,556	126,379,033	
Growth	n/a	48.8%	21.8%	-	-	14.2%	21.4%	21.4%	21.4%	21.3%	
EBITDA	(11,066,915)	(13,266,175)	(9,467,733)	(9,467,733)	(9,467,733)	(6,912,263)	(7,205,824)	(7,253,094)	(6,919,018)	(6,018,049)	(6,138,410)
Growth	(nmf)	(nmf)	nmf	(nmf)	(nmf)	nmf	(nmf)	(nmf)	nmf	nmf	2.0%
Depreciation & Amortization Expense	-	-	-	-	-	10,000,000	-	-	-	-	-
Interest Expense	-	-	-	-	-	-	-	-	-	-	-
Earnings Before Income Taxes	(11,066,915)	(13,266,175)	(9,467,733)	(9,467,733)	(9,467,733)	(16,912,263)	(7,205,824)	(7,253,094)	(6,919,018)	(6,018,049)	(6,138,410)
Federal & State Income Tax Expense	-	-	-	-	-	-	-	-	-	-	-
Earnings After Income Taxes	(\$11,066,915)	(\$13,266,175)	(\$9,467,733)	(\$9,467,733)	(\$9,467,733)	(\$16,912,263)	(\$7,205,824)	(\$7,253,094)	(\$6,919,018)	(\$6,018,049)	(\$6,138,410)

### STANFORD HEALTH CARE ADVANTAGE Scenario Value Calculation | Cash Flow Projections

						Projection Period					
	CY 2017	CY 2018	CY 2019	CY 2019	NBY	Year 1	Year 2	Year 3	Year 4	Year 5	Terminal Year
Revenues											
Premium Revenue	100.0%	100.0%	98.9%	98.9%	98.9%	99.1%	99.3%	99.4%	99.5%	99.6%	
Optional Supplemental Benefits	-	-	1.1%	1.1%	1.1%	0.9%	0.7%	0.6%	0.5%	0.4%	
Total Net Operating Revenue	100.0%	100.0%	100.0%	100.0%	100.0%	100.0%	100.0%	100.0%	100.0%	100.0%	100.0%
Operating Expenses											
Medical Expense	129.0%	120.5%	100.6%	100.6%	100.6%	98.5%	96.3%	94.2%	92.1%	90.0%	
General & Administrative	35.9%	25.9%	22.2%	22.2%	22.2%	15.0%	15.0%	15.0%	15.0%	15.0%	
Total Operating Expenses	164.9%	146.4%	122.8%	122.8%	122.8%	113.5%	111.3%	109.2%	107.1%	105.0%	
EBITDA	(64.9%)	(46.4%)	(22.8%)	(22.8%)	(22.8%)	(13.5%)	(11.3%)	(9.2%)	(7.1%)	(5.0%)	(5.0%)
Depreciation & Amortization Expense	-	-	-	-	-	19.5%	-	-	-	-	-
Interest Expense	-	-	-	-	-	-	-	-	-	-	-
Earnings Before Income Taxes	(64.9%)	(46.4%)	(22.8%)	(22.8%)	(22.8%)	(32.9%)	(11.3%)	(9.2%)	(7.1%)	(5.0%)	(5.0%)
Federal & State Income Tax Expense	-	-	-	-	-	-	-	-	-	-	-
Earnings After Income Taxes	(64.9%)	(46.4%)	(22.8%)	(22.8%)	(22.8%)	(32.9%)	(11.3%)	(9.2%)	(7.1%)	(5.0%)	(5.0%)

#### Scenario Value Calculation | Discounted Cash Flow Analysis

	Year 1	Year 2	Year 3	Year 4	Year 5	Terminal Year	Key Assumptions
EBITDA	(\$6,912,263)	(\$7,205,824)	(\$7,253,094)	(\$6,919,018)	(\$6,018,049)	(\$6,138,410)	
Depreciation & Amortization Expense	10,000,000	-	-	-	-	-	
Earnings Before Income Taxes	(16,912,263)	(7,205,824)	(7,253,094)	(6,919,018)	(6,018,049)	(6,138,410)	
Federal & State Income Tax Expense	-	-	-	-	-	-	28.0% Blended Federal & State Tax Rate
Earnings After Income Taxes	(16,912,263)	(7,205,824)	(7,253,094)	(6,919,018)	(6,018,049)	(6,138,410)	
Plus: Depreciation & Amortization	10,000,000	-	-	-	-	-	
Less: Required Annual Capital Expenditures	(10,000,000)	-	-	-	-	-	
Less: Incremental Working Capital Requirements	(1,044,260)	(1,293,843)	(1,603,077)	(1,986,219)	(2,460,933)	(256,135)	10.6% of Total Net Operating Revenues
Net Discretionary Cash Flow	(17,956,523)	(8,499,666)	(8,856,171)	(8,905,237)	(8,478,982)	(6,394,545)	
				Indicated	Residual Value:	(49,188,810)	2.0% Long-Term Growth Rate
Present Value Period (Mid-Year Convention)	0.50	1.50	2.50	3.50	4.50	4.50	
Present Value Factor	0.9325	0.8109	0.7051	0.6131	0.5332	0.5332	15.0% Weighted Average Cost of Capital
Discounted Net Discretionary Cash Flows	(\$16,744,544)	(\$6,892,156)	(\$6,244,553)	(\$5,460,131)	(\$4,520,677)	(\$26,225,636)	
Sum of the Present Value of the Years One through Five Pr	ojected Cash Flows				(\$39,862,061)	-	
Present Value of the Terminal Year					(\$26,225,636)	-	
Mid-Point Scenario Value Indication					nmf	-	

Please note, VMG did not rely on the value indication produced by the Income Approach due to the projected negative cash flows. Management indicated the operations of the Business are unlikely to yield positive cash flow in absence of increased membership growth to leverage the existing administrative expenses. Further, management indicated that the necessary membership growth is unlikely given the existing Stanford Health Care facility and provider network.



# **WE VALUE HEALTHCARE**

#### **Contact Us:**

(214) 369-4888

info@vmghealth.com



- () 2515 McKinney Avenue, Suite 1500, Dallas, TX 75201
- **?** 200 Columbine Street, Suite 350, Denver, CO 80206
- 150 3rd Avenue South, Suite 2120, Nashville, TN 37201